1、 陶泽宇,徐志,冯连顺,等. 治疗慢性乙型肝炎病毒感染药物的研究进展[J]. 国外医药(抗生素分册), 2018, 39(4): 308-319. 陶泽宇,徐志,冯连顺,等. 治疗慢性乙型肝炎病毒感染药物的研究进展[J]. 国外医药(抗生素分册), 2018, 39(4): 308-319.
2、 YANGW,SONG Y,LU Y L. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia[J].Immunology,2013,139(4):513-522. YANGW,SONG Y,LU Y L. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia[J].Immunology,2013,139(4):513-522.
3、 魏雪敏,隋龙. HPV感染后宫颈局部免疫环境改变及NO的作用[J].国际妇产科学杂志,2011,38(1):37-40. 魏雪敏,隋龙. HPV感染后宫颈局部免疫环境改变及NO的作用[J].国际妇产科学杂志,2011,38(1):37-40.
4、 SNOECK R, NOEL J C, MULLER C, et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)[J]. J Med Virol, 2000, 60(2): 205-209. SNOECK R, NOEL J C, MULLER C, et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)[J]. J Med Virol, 2000, 60(2): 205-209.
5、 KABAN I, CENGIZ H, KABAN A, et al. Agreement between colposcopy results using the Reid Colposcopic Index and histopathology[J]. Ginekologiapolska, 2015, 86(7): 537-540. KABAN I, CENGIZ H, KABAN A, et al. Agreement between colposcopy results using the Reid Colposcopic Index and histopathology[J]. Ginekologiapolska, 2015, 86(7): 537-540.
6、 LIN C, QIU J, WANG C, et al. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia[J]. Taiwan J Obstet Gynecol, 2012, 51(4): 533-538. LIN C, QIU J, WANG C, et al. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia[J]. Taiwan J Obstet Gynecol, 2012, 51(4): 533-538.
7、 HAMPSON L, MARTIN-HIRSCH P, HAMPSON I N, et al. An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia[J]. Expert OpinInvestig Drugs, 2015, 24(12): 1529-1537. HAMPSON L, MARTIN-HIRSCH P, HAMPSON I N, et al. An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia[J]. Expert OpinInvestig Drugs, 2015, 24(12): 1529-1537.
8、 刘嵘,祝达,李天,等. 二黄栓治疗高危型H PV持续阳性宫颈病变的临床疗效观察及机制探讨[J]. 华中科技大学学报(医学版), 2018, 47(3):325-328. 刘嵘,祝达,李天,等. 二黄栓治疗高危型H PV持续阳性宫颈病变的临床疗效观察及机制探讨[J]. 华中科技大学学报(医学版), 2018, 47(3):325-328.
9、 赵健,廖秦平,谢红,等. 保妇康栓治疗人乳头瘤病毒感染的临床观察[J]. 实用妇产科杂志, 2015, 31(1): 45-48. 赵健,廖秦平,谢红,等. 保妇康栓治疗人乳头瘤病毒感染的临床观察[J]. 实用妇产科杂志, 2015, 31(1): 45-48.
10、 HILLEMANNS P, PETRY K U, SOERGEL P, et al. Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia[J]. Lasers Surg Med, 2014, 46(6): 456-461. HILLEMANNS P, PETRY K U, SOERGEL P, et al. Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia[J]. Lasers Surg Med, 2014, 46(6): 456-461.
11、 KYRGIOU M, KOLIOPOULOS G, MARTIN-HIRSCH P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis[J]. Lancet, 2006, 367(9509): 489-498. KYRGIOU M, KOLIOPOULOS G, MARTIN-HIRSCH P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis[J]. Lancet, 2006, 367(9509): 489-498.
12、 INSINGA R P, DASBACH E J, ELBASHA E H, et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women[J]. Infect Agent Cancer,2007(2): 15. INSINGA R P, DASBACH E J, ELBASHA E H, et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women[J]. Infect Agent Cancer,2007(2): 15.
13、 FU Y, BAO Y, HUI Y, et al. Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection[J]. Photodiagnosis Photodyn Ther, 2016,(13): 29-33. FU Y, BAO Y, HUI Y, et al. Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection[J]. Photodiagnosis Photodyn Ther, 2016,(13): 29-33.
14、 van PACHTERBEKE C, BUCELLA D, ROZENBERG S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study[J]. Gynecol Oncol, 2009, 115(1): 69-74. van PACHTERBEKE C, BUCELLA D, ROZENBERG S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study[J]. Gynecol Oncol, 2009, 115(1): 69-74.
15、 韩芳,陆巧妮,徐力昆,等. 西多福韦对人宫颈癌细胞CaSki内人乳头瘤病毒16抑制作用研究[J]. 中国医药生物技术, 2014(5): 347-352. 韩芳,陆巧妮,徐力昆,等. 西多福韦对人宫颈癌细胞CaSki内人乳头瘤病毒16抑制作用研究[J]. 中国医药生物技术, 2014(5): 347-352.
16、 de CLERCQ E. In search of a selective therapy of viral infections[J]. Antiviral Res, 2010, 85(1): 19-24. de CLERCQ E. In search of a selective therapy of viral infections[J]. Antiviral Res, 2010, 85(1): 19-24.
17、 European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
18、 TERRAULT N A, LOK A, MCMAHON B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. TERRAULT N A, LOK A, MCMAHON B J, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599.
19、 HILDESHEIM A, HERRERO R, WACHOLDER S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial[J]. JAMA, 2007, 298(7): 743-753. HILDESHEIM A, HERRERO R, WACHOLDER S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial[J]. JAMA, 2007, 298(7): 743-753.
20、 CASTLE P E, RODRIGUEZ A C, BURK R D, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study[J]. BMJ, 2009, 339: b2569. CASTLE P E, RODRIGUEZ A C, BURK R D, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study[J]. BMJ, 2009, 339: b2569.
21、 EBISCH R, KETELAARS P, van der SANDEN W, et al. Screening for persistent high-risk HPV infections may be a valuable screening method for young women: A retrospective cohort study[J]. PLoS One, 2018, 13(10): e206219. EBISCH R, KETELAARS P, van der SANDEN W, et al. Screening for persistent high-risk HPV infections may be a valuable screening method for young women: A retrospective cohort study[J]. PLoS One, 2018, 13(10): e206219.
22、 ZHOU H L, ZHANG W, ZHANG C J, et al. Prevalence and distribution of human papillomavirus genotypes in Chinese women between 1991 and 2016: a systematic review[J]. J Infect, 2018, 76(6): 522-528. ZHOU H L, ZHANG W, ZHANG C J, et al. Prevalence and distribution of human papillomavirus genotypes in Chinese women between 1991 and 2016: a systematic review[J]. J Infect, 2018, 76(6): 522-528.
